1. Home
  2. ACAD vs NG Comparison

ACAD vs NG Comparison

Compare ACAD & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.69

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Novagold Resources Inc.

NG

Novagold Resources Inc.

HOLD

Current Price

$8.16

Market Cap

4.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
NG
Founded
1993
1984
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.1B
IPO Year
2000
2002

Fundamental Metrics

Financial Performance
Metric
ACAD
NG
Price
$22.69
$8.16
Analyst Decision
Buy
Strong Buy
Analyst Count
22
6
Target Price
$30.55
$12.22
AVG Volume (30 Days)
1.4M
2.9M
Earning Date
05-06-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
69.12
N/A
EPS
2.30
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
N/A
Revenue Next Year
$11.70
N/A
P/E Ratio
$9.71
N/A
Revenue Growth
40.45
N/A
52 Week Low
$14.18
$3.37
52 Week High
$28.35
$14.40

Technical Indicators

Market Signals
Indicator
ACAD
NG
Relative Strength Index (RSI) 56.45 37.24
Support Level $19.87 $7.85
Resistance Level $22.97 $10.44
Average True Range (ATR) 0.65 0.55
MACD 0.11 -0.13
Stochastic Oscillator 97.81 2.47

Price Performance

Historical Comparison
ACAD
NG

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About NG Novagold Resources Inc.

Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.

Share on Social Networks: